



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 022259-001010US

FW

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On 04-27-06

TOWNSEND and TOWNSEND and CREW LLP  
By:   
Katherine Farkas  


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Hideki GARREN et al.

Application No.: 10/524,643

Filed: February 10, 2005

For: METHODS AND IMMUNE  
MODULATORY NUCLEIC ACID  
COMPOSITIONS FOR PREVENTING  
AND TREATING DISEASE

Confirmation No.: 1611

Examiner: Unassigned

Art Unit: 1645

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A&B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:klf  
60757998 v1



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/524,643
				Filing Date	February 10, 2005
				First Named Inventor	Hideki GARREN
				Art Unit	1645
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	022259-001010US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-6,194,388 B1	02-27-2001	Krieg et al.	
	2	US-6,225,292 B1	05-01-2001	Raz et al.	
	3	US-2002/0164341 A1	11-07-2002	Davis et al.	
	4	US-2003/0181406 A1	09-25-2003	Schetter et al.	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	5	HO et al., "An immunomodulatory CpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems", <u>J. Immunology</u> , 2003, pp. 4920-4926, Vol. 171.	<input checked="" type="checkbox"/>	
	6	KLINMAN et al., "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon $\gamma$ ", <u>Proc Nat. Acad. U.S.A.</u> , 1996, pp. 2879-2883, Vol. 93.	<input checked="" type="checkbox"/>	
	7	KRIEG et al., "CpG motifs in bacterial DNA trigger direct B-Cell activation", <u>Nature</u> , 1995, pp. 546-549, Vol. 374.	<input checked="" type="checkbox"/>	
	8	MARTIN-OROZCO et al., "Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences", <u>Int. Immunol.</u> , 1999, pp. 1111-1118, Vol. 11(7).	<input checked="" type="checkbox"/>	
	9	SPARWASSER et al., "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells", <u>Eur. J. Immunol.</u> , 1998, pp. 2045-2054, Vol. 28.	<input checked="" type="checkbox"/>	
	10	STACEY et al., "Immunostimulatory DNA as an adjuvant in vaccination against <i>Leishmania major</i> ", <u>Infection and Immunity</u> , 1999, pp. 3719-3726, Vol. 67(8).	<input checked="" type="checkbox"/>	
	11	YI et al., "Rapid Immune Activation by CpG Motifs in Bacterial DNA", <u>J. Immunol.</u> , 1996, pp. 5394-5402, Vol. 157.	<input checked="" type="checkbox"/>	
	12	ZEUNER et al., "Reduction of CpG-Induced Arthritis by Suppressive Oligodeoxynucleotides", <u>Arthritis and Rheumatism</u> , 2002, pp. 2219-2224, Vol. 46(8).	<input checked="" type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if reference is attached.